Cystic Fibrosis

Cystic fibrosis

'Groundbreaking': Cystic fibrosis drug is safe and effective in newborns

New research has shown that Ivacaftor, also known as Kalydeko, is a safe and effective treatment for cystic fibrosis in newborns. This groundbreaking discovery means that the drug, previously only available to babies aged four months or older, can now be used to help even younger patients.

This development is a significant step forward in the treatment of cystic fibrosis, offering hope to families and patients affected by this debilitating condition. The safety and effectiveness of Ivacaftor in newborns represents a major breakthrough in the fight against cystic fibrosis, providing new treatment options for those in need.